<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060786</url>
  </required_header>
  <id_info>
    <org_study_id>Plavitor</org_study_id>
    <nct_id>NCT02060786</nct_id>
  </id_info>
  <brief_title>Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)</brief_title>
  <official_title>Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study demonstrates the effect of generic clopidogrel bisulfate (Plavitor®) in comparison
      with the original clopidogrel bisulfate (Plavix®) in patients with acute coronary syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRU level at 2 hours after clopidogrel loading</measure>
    <time_frame>2 hours after clopidogrel loading</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRU level by VerifyNow P2Y12 at 4 -, 8- and 24 hours after clopidogrel loading</measure>
    <time_frame>4 -, 8- and 24 hours after clopidogrel loading</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARU level by VerifyNow before and 2 hours after loading</measure>
    <time_frame>2 hours after loading</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death, myocardial infarction, target vessel revascularization</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis by Academic Research Consortium definition</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TIMI major bleedings</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>original Clopidogrel Bisulfate (Plavix®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>original Clopidogrel Bisulfate (Plavix®) 600mg loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic Clopidogrel Bisulfate (Plavitor®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic Clopidogrel Bisulfate (Plavitor®) 600mg loading</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic clopidogrel (Plavitor® )</intervention_name>
    <arm_group_label>generic Clopidogrel Bisulfate (Plavitor®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>original clopidogrel (Plavix® )</intervention_name>
    <arm_group_label>original Clopidogrel Bisulfate (Plavix®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with unstable angina or non-ST elevation myocardial infarction

          2. Patients who are planned coronary angiography

          3. Age &gt;18 years, &lt;75 years

          4. Patients who agree to the study protocol

        Exclusion Criteria:

          1. Recent treatment with clopidogrel or pletaal or glycoprotein IIb/IIIa Rc antagonist

          2. Active bleeding (peptic ulcer, trauma or intra-cranial hemorrhage)

          3. Allergy to antiplatelet agent

          4. Bleeding diasthesis (blood coagulation disorders, uncontrolled severe hypertension,
             history of severe bleeding)

          5. History of drug abuse or alcohol abuse

          6. ST elevation myocardial infarction

          7. Pregnancy

          8. Low platelet count (&lt; 100,000 /L) or abnormal results of PT or PTT

          9. Liver disease ( bilirubin &gt; 2 mg/dL, AST or ALT &gt; 100 IU)

         10. Renal failure ( Cr &gt; 2.0 mg/dL)

         11. Malignancy

         12. Proton pump inhibitor, NSAIDs statin (except atorvastatin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Seung-Jea Tahk</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Antiplatelet; clopidogrel; acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

